Twist Bioscience Corporation

TWST

US90184D1000

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-10 pm EDT			5-day change	1st Jan Change
50.99 ^USD	+0.97%		+6.23%	+38.33%

Jul. 09	Goldman Sachs Raises Price Target on Twist Bioscience to $55 From $45, Maintains Buy Rating	MT
Jul. 09	Twist Bioscience Launches Synthetic RNA Control for H5N1 Influenza A	MT

Twist Bioscience Corporation(NasdaqGS:TWST) dropped from Russell 2500 Value Index

July 30, 2024

Latest news about Twist Bioscience Corporation

Goldman Sachs Raises Price Target on Twist Bioscience to $55 From $45, Maintains Buy Rating	Jul. 09	MT
Twist Bioscience Launches Synthetic RNA Control for H5N1 Influenza A	Jul. 09	MT
Twist Bioscience Corporation Launches Synthetic RNA Control for H5N1 Influenza A	Jul. 09	CI
Twist Bioscience Corporation(NasdaqGS:TWST) dropped from Russell 3000E Value Index	Jun. 30	CI
Twist Bioscience Corporation(NasdaqGS:TWST) dropped from Russell 3000 Value Index	Jun. 30	CI
Twist Bioscience Corporation(NasdaqGS:TWST) dropped from Russell 2500 Value Index	Jun. 30	CI
Twist Bioscience Corporation(NasdaqGS:TWST) dropped from Russell Small Cap Comp Value Index	Jun. 30	CI
Twist Bioscience Corporation(NasdaqGS:TWST) added to Russell 3000 Growth Index	Jun. 30	CI
Twist Bioscience Corporation(NasdaqGS:TWST) dropped from Russell 2000 Value Index	Jun. 30	CI
Twist Bioscience Corporation(NasdaqGS:TWST) added to Russell 3000E Growth Index	Jun. 30	CI
Twist Bioscience Corporation(NasdaqGS:TWST) added to Russell 2000 Growth Index	Jun. 30	CI
Twist Bioscience Corporation(NasdaqGS:TWST) added to Russell 2500 Growth Index	Jun. 30	CI
Twist Bioscience Corporation(NasdaqGS:TWST) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Barclays Adjusts Price Target on Twist Bioscience to $60 From $45, Maintains Overweight Rating	Jun. 28	MT
Transcript : Twist Bioscience Corporation Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10:00 AM	Jun. 11
Twist Bioscience Publishes Preclinical Data Detailing Discovery of Antibody Targeting Emerging Checkpoint Inhibitor	Jun. 06	CI
Guggenheim Initiates Twist Bioscience With Buy Rating, $53 Price Target	Jun. 04	MT
Oxford Nanopore Technologies Collaborates with Twist Bioscience to Launch Pharmacogenomics Beta Programme and Advance Personalised Medicine	May. 22	CI
Twist Bioscience Launches Multiplexed Gene Fragments to Enable High-Throughput Screening Applications	May. 13	CI
Sector Update: Health Care Stocks Mixed Late Afternoon	May. 03	MT
Sector Update: Health Care Stocks Mixed in Afternoon Trading	May. 03	MT
Twist Bioscience Shares Jump After Fiscal Q2 Beat, Fiscal 2024 Revenue Guidance Raised	May. 03	MT
Transcript : Twist Bioscience Corporation, Q2 2024 Earnings Call, May 02, 2024	May. 02
Earnings Flash (TWST) TWIST BIOSCIENCE CORPORATION Posts Q2 Revenue $75.3M, vs. Street Est of $70.8M	May. 02	MT
Twist Bioscience Corporation Revises Earnings Guidance for the Fiscal Year 2024	May. 02	CI

Chart Twist Bioscience Corporation

Duration

Period

More charts

Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that develops manufacturing synthetic DNA by writing DNA on a silicon chip. The Company leverages its technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation and antibody libraries for drug discovery and development. It has miniaturized traditional chemical DNA synthesis reactions to write over one million short pieces of DNA on each silicon chip. It offers two product lines: synthetic biology tools and NGS tools, that address different needs of its customers across a variety of applications. It offers ribonucleic acid and protein products. Its synthetic biology products include synthetic genes and gene fragments, and oligonucleotide or oligo pools.

Sector

Pharmaceuticals

Calendar

2024-08-01 - Q3 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Twist Bioscience Corporation

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

50.5 USD

Average target price

48.33 USD

Spread / Average Target

-4.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
TWIST BIOSCIENCE CORPORATION	+38.33%	2.94B
CSL LIMITED	+3.84%	97.02B
SAMSUNG BIOLOGICS CO.,LTD.	+6.18%	40.94B
BIOGEN INC.	-10.06%	33.35B
UCB	+83.78%	29.53B
BIOMARIN PHARMACEUTICAL INC.	-14.65%	15.76B
INCYTE CORPORATION	-3.28%	13.65B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.70%	11.44B
ALTEOGEN INC.	+174.11%	10.08B
SWEDISH ORPHAN BIOVITRUM AB	+6.14%	9.06B

Biopharmaceuticals